Table 1.

Clinical and biological characterization of the sample (n = 362)

Variable	Total study sample
Gender (n = 362), n (%)
Male	228 (63.0)
Female	134 (37.0)
Age (years) (n = 361), med (IQR)	42 (31.0–53.5)
Age categories (years) (n = 361), n (%)
≤ 18	19 (5.3)
19–40	152 (42.1)
41–64	98 (43.5)
> 65	18 (9.1)
SARS-CoV-2 infection (n = 361), n (%)
Yes	114 (31.7)
No	247 (68.3)
SARS-CoV-2 infection period (date) (n = 106), min–max	February 2020 to January 2021
Analysis period (date) (n = 360), min–max	April 2020 to February 2021
Days from diagnosis till analysis (n = 105), med (IQR) (min–max)	60.0 (33.5–110.0) (7–340)
Exposure to a positive case (n = 337), n (%)
Yes	133 (39.5)
No/Do not know	204 (60.5)
Symptoms of COVID-19 (n = 318), n (%)
Yes (one or more)	62 (19.3)
No	256 (79.8)

Med (IQR): median (interquartile range); n (%): count (percentage); min–max: minimum–maximum